News coverage about Endologix (NASDAQ:ELGX) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endologix earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.9778739381029 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Endologix Gains on Test Results (baystreet.ca)
- -$0.19 Earnings Per Share Expected for Endologix, Inc. (ELGX) This Quarter (americanbankingnews.com)
- BRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm Repair (reuters.com)
- Endologix (ELGX) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
- 7 Stocks Moving In Monday’s After-Hours Session (feeds.benzinga.com)
ELGX has been the subject of several research analyst reports. JPMorgan Chase & Co. lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Oppenheimer set a $5.00 price target on shares of Endologix and gave the company a “hold” rating in a report on Thursday, February 22nd. ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. BidaskClub lowered shares of Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.41.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.13. The business had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.91 million. Endologix had a negative net margin of 36.65% and a negative return on equity of 44.91%. The firm’s revenue was down 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) EPS. equities research analysts predict that Endologix will post -0.61 EPS for the current fiscal year.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.